|
Post by patten1962 on Jul 4, 2016 16:25:11 GMT -5
SNY has been laying off sales people last 6 months .... It would be nice to find a few disgruntled former SNY sales reps to talk about their instructions regarding Afrezza .... My guess is Matt and his team has already done that!
|
|
|
Post by matt on Jul 5, 2016 7:14:22 GMT -5
It is great to fantasize about suing Sanofi, but the realities are far different from the fantasy. Even if this were to go to arbitration as the contract requires, the burden of proof is still on Mannkind to show that Sanofi did not meet the minimal requirements of the contract. Sanofi spent enough money to show that they had made "commercially reasonable" efforts. The standard is not that they did everything perfectly or that they could have done more, it is whether the efforts were reasonable. In that kind of a pissing contest, Sanofi would have the upper hand.
What really matters now is whether this company can sell Afrezza on their own or not, because if they can't the company will go belly-up. The company has little cash on the balance sheet, a ton of senior debt, and a depressed share price relative to past years. Do shareholders really want their management to spent their time and precious cash chasing Sanofi in arbitration or do you want that energy focused on the job at hand?
|
|
|
Post by anderson on Jul 5, 2016 8:38:15 GMT -5
The real proof would be if MNKD can take Afrezza to blockbuster status in a years time with this small team and meager resources. That would then raise questions about why could MNKD do and a large company like SNY couldnt. Right now it is just a waste of MNKD's resources to try and push SNY for anything. So basically if MNKD does incredibly well and they have the cash to chase SNY in a multi year boondoggle they might do it for the publicity, but in the end monetarily it would be way after the time it is needed and at that time not very big to MNKD's bottom line. The best way to get revenge on SNY is to promote Tresiba + Afrezza combo and take market share. Then pour money into Technovax and take market share from Sanofi pasteur. I believe those are the two of the largest divisions they have so that would hurt them. en.sanofi.com/investors/key_facts_figures/key_facts_figures.aspx. Total Pharmaceuticals €29,799M with Diabetes €7,580M, and Vaccines €4,743M. That would in the long run be about 40% of SNY's business. So lets just forget about lawsuits that will take years and put that money into research and get our revenge by taking market share(since both will take year might as well go with the one with the most impact).
|
|
|
Post by agedhippie on Jul 5, 2016 8:50:55 GMT -5
The real proof would be if MNKD can take Afrezza to blockbuster status in a years time with this small team and meager resources. That would then raise questions about why could MNKD do and a large company like SNY couldnt. Right now it is just a waste of MNKD's resources to try and push SNY for anything. So basically if MNKD does incredibly well and they have the cash to chase SNY in a multi year boondoggle they might do it for the publicity, but in the end monetarily it would be way after the time it is needed and at that time not very big to MNKD's bottom line. The best way to get revenge on SNY is to promote Tresiba + Afrezza combo and take market share. Then pour money into Technovax and take market share from Sanofi pasteur. I believe those are the two of the largest divisions they have so that would hurt them. en.sanofi.com/investors/key_facts_figures/key_facts_figures.aspx. Total Pharmaceuticals €29,799M with Diabetes €7,580M, and Vaccines €4,743M. That would in the long run be about 40% of SNY's business. So lets just forget about lawsuits that will take years and put that money into research and get our revenge by taking market share(since both will take year might as well go with the one with the most impact). If Mannkind can take Afrezza to blockbuster status in a year it would prove that Sanofi took the wrong approach - but that is not a breach of contract so arbitration would fail. Pursuing Sanofi for publicity would be a complete waste of time everything to do with arbitration from threat to award is confidential and exposing any of that would be a breach of contract. Promoting Tresiba + Afrezza runs into problems. Now you are trying to sell a competitors product and one that has patchy insurance cover at that. I would rather we concentrated our marketing budget on Mannkind products rather than subsidize Novo Nordisk's marketing budget.
|
|